Shanghai, China/San Diego, USA, September 16, 2022 - ABM Therapeutics, invested and incubated by Viva BioInnovator, a clinical-stage biopharmaceutical company, today announced that the first patient has been successfully dosed with ABM-1310 in a multi-center phase I clinical trial in China.
ABM-1310, the company’s proprietary clinical candidate developed as a next-generation BRAF inhibitor, demonstrated superior properties in pre-clinical animal models for treating cancer brain metastases, is a highly selective, highly water-soluble, orally active, and brain-penetrant small molecule BRAF inhibitor. Dosing the first patient in China represents another milestone for ABM-1310, which has been carrying out in several well-known cancer centers in the United States. The US Phase I trial has demonstrated a good safety profile and efficacy signals.
“Dosing the first patient in China is of great clinical significance both for ABM-1310 program and for patients. We are humbly grateful to patients and their families, investigators and clinical study sites for their trusts, supports and anticipation on the study.” Dr. Chen Chen, founder and CEO of ABM Therapeutics, said: “Brain metastasis is a commonly fatal event to many cancer patients; however, current treatment options are very limited. We are developing drugs that can fulfill the unmet medical needs. We are at full steam pushing forward the clinical development of ABM-1310, with passion to bring the potential therapeutic benefits to patients.”
ABM-1310 phase I trial, conducted in China, is a multi-center, open-label study to investigate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of ABM-1310 in Chinese patients with BRAF V600X mutated advanced solid tumors with the goal to determine the optimal/recommended dose for phase 2 studies.
As a clinical-stage biotechnology company, ABM Therapeutics has got a broad and robust proprietary pipeline to construct a Brain-Penetrant Kinase Drug Discovery Platform (BPKddTM）. It will continue to focus on the small molecule research and development of novel drugs for the treatment of cancer, with an emphasis on blood–brain barrier (BBB) penetration and brain metastases. We look forward to working with international pharmaceutical companies and biotech companies from multiple perspectives and making our drugs to benefit more patients in the world.
ABM-1310, the first drug candidate of ABM Therapeutics, is a highly water-soluble and cell/brain-permeable BRAF inhibitor for the treatment of cancers with BRAF V600X oncogenic driver, with or without brain metastases. ABM-1310 significantly prolonged animal median survival time in the preclinical models of brain metastases and is expected to treat various malignant tumors and brain metastases. It was granted clearance of the Investigational New Drug (IND) application to proceed with the first-in-human clinical trial on November 29, 2019 by the US FDA (clinical trial information: NCT04190628). More information about ABM’s ongoing ABM-1310 trial is available at www.ClinicalTrials.gov and on the company website at www.abmtx.com.
About ABM Therapeutics
ABM Therapeutics, a clinical-stage biopharmaceutical company with a mission to focus on the small molecule research and development of novel drugs for the treatment of cancer, and on brain cancer and cancer metastases. ABM has been building its broad and robust proprietary pipeline to construct a brain medicine R&D platform through collaboration with CROs. ABM’s pipeline includes several programs in various stages of discovery and development, most of which have improved brain permeability to address the unmet needs of treating cancers and metastases in the brain.